GlobalData analyst Dr Andrew S Thompson expects the deal to prompt a "shuffle" in Thermo Fisher’s life sciences unit.

Trian Fund Management, L.P. (“Trian”), which beneficially owns ~5% of Solventum Corporation (NYSE: SOLV) (“Solventum” or the “Company”) and is the Company’s largest active shareholder, commented on ...

Thermo Fisher Scientific is expanding its life sciences portfolio by acquiring a division of Solventum that provides ...

Trian Fund Management, which beneficially owns about 5% of Solventum (SOLV) and is the company’s largest active shareholder, commented on ...

Activist investor Nelson Peltz's Trian Fund Management plans to push Solventum for further business separations following the company's $4.1 billion filtration unit sale, the Wall Street Journal ...

BofA raised the firm’s price target on Solventum (SOLV) to $85 from $80 and keeps a Neutral rating on the shares after the company agreed to ...

Thermo Fisher Scientific has a market capitalization of about $203.5 billion. Shares (NYSE: TMO) at midday Wednesday were trading around $532, which is near the bottom of their 52-week range.

Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare ...

Investing.com -- Activist investor Trian Fund Management is reportedly planning to urge Solventum to separate additional businesses following the company's $4.1 billion deal to sell its filtration ...

Thermo Fisher Scientific is buying Solventum’s purification & filtration unit for $4.1 billion in cash, strengthening its ...

There’s still a dearth of mega deals. The largest deal from the past week was Sun Communities (Latham & Watkins advising) ...

Solventum's $4.1B divestment to Thermo Fisher enhances financial stability, boosts EPS, and strengthens its long-term growth ...